NACDS pledges to award at least $100,000 in scholarships
ALEXANDRIA, Va. The National Association of Chain Drug Stores Foundation is pledging to award at least $100,000 this year in scholarships, and has begun accepting applications.
Last year, 40 students were awarded a scholarship, an increase of three from 2005, and this year it looks like the foundation wants to add award the scholarship of $2,000 to at least 50 students. Also, some select recipients will receive named scholarships in the amount of $2,500, in addition to the $2,000 scholarship.
Applicants must be at least in their second year of pharmacy school, as well as have experience and the desire to work in a chain community pharmacy.
“The NACDS Foundation is continuously committed to advancing the pharmacy industry for the good of the public. An important part of our industry is its future, and that is what these students represent,” said Phil Schneider, NACDS Foundation president. The deadline for all applications is Oct. 19.
Roche to sue Teva over patent of Boniva
BASEL, Switzerland Swiss pharmaceutical company Roche Holding has filed suit against generic pharmaceutical maker Teva over Roche’s patented osteoporosis treatment, the company said Tuesday.
Roche filed a complaint at a New Jersey district court to prevent Teva from selling their generic version of Boniva, the company’s spokeswoman said.
Sales of Boniva for the first six months of the year totaled $314 million. Recently, Roche’s rival Novartis filed for an injunction against the generic pharmaceutical maker to halt the creation and production of its Famvir herpes treatment. Novartis was denied the injunction but was granted one by the U.S. District Court of Appeals a few days later.
King Pharma announces intention to fight Actavis’ generic Avinza
BRISTOL, Tenn. King Pharmaceuticals has recently learned that Actavis has filed paperwork with the Food and Drug Administration to make a generic version of their pain medication Avinza (morphine sulfate).
King “intends to vigorously enforce the patent on Avinza” by starting legal procedures that will most likely ending up with the two companies meeting in federal court. King spokesman James Green said, “The business of generic manufacturers is to challenge as many patents as possible, hoping to win a few.”
At the beginning of the year King acquired all the rights to Avinza from Ligand Pharmaceuticals and has seen revenues of $9 million and $35 million in the first and second quarters of 2007.
Avinza’s patent does not end until Nov. 25, 2017.